可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] 王松男,张玉东. 他汀类药物对冠心病强化降脂的研究进展[J]. 心脏杂志, 2007, 19(4):488-490.
[2] Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes[J]. J Am Coll Cardiol, 2005, 46(8):1425-1433.
[3] Ito MK, Talbert RL, Tsimikas S. Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction[J]. Pharmacotherapy, 2006, 26(7 Pt 2):85S-97S.
[4] 钟萍,陈姗. 普伐他汀的非降脂作用[J]. 心脏杂志, 2006, 18(6):664-665,671.
[5] Atar S, Ye Y, Lin Y, et al. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2[J]. Am J Physiol Heart Circ Physiol, 2006, 290(5):H1960-H1968.
[6] Di Napoli P, Taccardi AA, Grilli A, et al. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts[J]. Cardiovasc Res, 2005, 66(3):462-471.
[7] Verma S, Rao V, Weisel RD, et al. Novel cardioprotective effects of pravastatin in human ventricular cardiomyocytes subjected to hypoxia and reoxygenation: beneficial effects of statins independent of endothelial cells[J]. J Surg Res, 2004, 119(1):66-71.
[8] 张晓捷,孙宗全,杜心灵. 洛伐他汀预处理的延迟性心肌保护作用及机制[J]. 心脏杂志, 2006, 18(1): 50-53.
[9] 周逸,唐其柱. ATP敏感性钾通道在缺血预适应中的作用[J]. 心脏杂志, 2005, 17(1): 83-86.
[10]O’Rourke B. Evidence for mitochondrial K+ Channels and their role in cardioprotection[J]. Circ Res, 2004, 94(5):420-432.
[11]Tavackoli S, Ashitkov T, Hu ZY, et al. Simvastatin-induced myocardial protection against ischemia-reperfusion injury is mediated by activation of ATP-sensitive K+ channels[J]. Coron Artery Dis, 2004, 15(1):53-58.
[12]Zhao ZQ, Zang YM. Alternative cardioprotective strategy during reperfusion: Postconditioning vs Preconditioning[J]. 心脏杂志, 2006, 18(1):1-7,13.